Carvajal, Richard D. http://orcid.org/0000-0002-3796-1118
Butler, Marcus O. http://orcid.org/0000-0002-9840-7057
Shoushtari, Alexander N. http://orcid.org/0000-0002-8065-4412
Hassel, Jessica C.
Ikeguchi, Alexandra http://orcid.org/0000-0002-4448-9755
Hernandez-Aya, Leonel
Nathan, Paul
Hamid, Omid
Piulats, Josep M.
Rioth, Matthew
Johnson, Douglas B. http://orcid.org/0000-0002-6390-773X
Luke, Jason J.
Espinosa, Enrique
Leyvraz, Serge
Collins, Laura
Goodall, Howard M.
Ranade, Koustubh
Holland, Chris
Abdullah, Shaad E. http://orcid.org/0000-0003-0776-7477
Sacco, Joseph J. http://orcid.org/0000-0003-2591-9796
Sato, Takami http://orcid.org/0000-0003-2221-0415
Article History
Received: 4 April 2022
Accepted: 16 August 2022
First Online: 13 October 2022
Competing interests
: R.D.C. discloses consulting: Alkermes, BMS, Castle Biosciences, Delcath, Eisai, Hengrui, Ideaya, Immunocore, InxMed, Iovance, Merck, Novartis, Oncosec, Pierre Fabre, PureTech Health, Regeneron, Sanofi Genzyme, Sorrento Therapeutics, Trisalus; clinical/scientific advisory boards: Aura Biosciences, Chimeron, Rgenix. M.O.B. discloses advisory/consulting: Merck, BMS, Novartis, Sanofi, Pfizer, Adaptimmune, GSK, Immunocore, EMD Serono, Sun Pharma, Medison, Instil Bio, IOVANCE; research funding to self: Merck, Takara Bio; research funding to institution: Merck, BMS, Novartis, Sanofi, Adaptimmune, Immunocore, Regeneron, Lilly, Amgen, OncoSeq; Speaker: BMS, Merck, Pfizer, Novartis, Sanofi. A.N.S. discloses honoraria advisory board/personal fees: BMS, Castle Biosciences, Immunocore, Novartis; licensing/royalties: UpToDate; research funding to institution: BMS, Checkmate Pharmaceuticals, Foghorn Therapeutics, GSK, Immunocore, Novartis, Pfizer, Polaris, Targovax, Xcovery. J.C.H. discloses advisory boards (self): GSK, MSD, Pierre Fabre, Sun Pharma; advisory boards (institution): BMS, Immunocore, Novartis, Nektar, Philogen; contracted research: 4SC, BioNTech, BMS, Genentech/Roche, Idera, Immunocore, Iovance, Nektar, Novartis, Philogen, Pierre Fabre, Regeneron, Sanofi; honoraria: BMS, MSD, Novartis, Pierre Fabre, Roche, Sanofi, Sun Pharma; research funding to institution: BMS, Sun Pharma. A.I. discloses research funding to institution: Checkmate Pharmaceuticals, Dynavax, GSK/Sarah Cannon, Immunocore, Merck, Neon Therapeutics/Sarah Cannon. L.H.-A. discloses advisory/consulting: BMS, Castle Bioscience; research funding to institution: BMS, AstraZeneca, Merck, Amgen, Roche, Regeneron, Novartis, Immunocore, Merck-EMD, Corvus, Polynoma, Genentech, Foghorn. P.N. discloses advisory/consulting: BMS, Immunocore, Ipsen, Incyte, MSD, Merck, Novartis, Pfizer, 4SC; speaker’s bureau: BMS, Merck, Novartis, Pfizer; research funding to institution: Immunocore, Novartis. O.H. discloses contracted research (institute): Aduro, Akeso, Amgen, Bioatla, BMS, Genentech, GSK, Idera, Immunocore, Incyte, Merck, NextCure, Novartis, Pfizer, Sanofi/Regeneron, SeaGen, Zelluna; speaker’s bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron; consulting/advisory board: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Genentech, GSK, Idera, Immunocore, Incyte, Janssen, Merck, NextCure, Novartis, Pfizer, Sanofi/Regeneron, SeaGen, Tempus, Zelluna. J.M.P. discloses research funding: BeiGene, BMS, Immunocore, Mirati, MSD. M.R. discloses consulting: Health Advances. D.B.J. discloses consultancy: BMS, Catalyst, Iovance, Janssen, Mallinckrodt, Merck, Mosaic, Novartis, Oncosec, Pfizer, Targovax, Teiko; non-remunerated activities: Melanoma Guideline Committee (NCCN), Scientific Selection Committee (ASCO), Immunotherapy Toxicity Guidelines (SITC); research funding to self: BMS, Incyte; research funding to institution: Array Biopharma, Genentech, Immunocore, Nektar. J.J.L. discloses consulting: Abbvie, Bayer, BMS, Castle, Checkmate, Codiak, Crown, Day One, Duke St, EMD Serono, Endeavor, Flame, Genentech, Gilead, Glenmark, HotSpot, Kadmon, Janssen, Ikena, Immunocore, Incyte, IO Biotech, Macrogenics, Merck, Nektar, Novartis, Partner, Pfizer, Regeneron, Roivant, Servier, STINGthera, Synlogic, Synthekine; scientific advisory board (no stock): 7 Hills, Bright Peak, Exo, Fstar, Inzen, RefleXion, Xilio; scientific advisory board (stock): Actym, Alphamab Oncology, Arch Oncology, Kanaph, Mavu, NeoTx, Onc.AI, OncoNano, Pyxis, STipe, Tempest; Data and Safety Monitoring Board: Abbvie, Immutep, Evaxion; research funding to institution: Abbvie, Astellas, AstraZeneca, BMS, Corvus, Day One, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics. Merck, Moderna, Nektar, NextCure, Numab, Palleon, Pfizer, Replimmune, Rubius, Servier, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, Xencor; patents (provisional): serial no. 15/612,657 (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof). E.E. discloses consulting: BMS, MSD, Novartis, Pierre Fabre; non-remunerated activities: Vice-President (Grupo Espanol Melanoma); speaker bureau: BMS, MSD, Novartis, Pierre Fabre. S.L. discloses consulting: Bayer, Immunocore; expenses: Bayer. L.C., H.M.G., K.R., C.H. and S.E.A. are employees and have stocks/shares or stock options in Immunocore, which could benefit from commercialization of these results. J.J.S. discloses advisory/consulting: Immunocore, BMS, MSD, Delcath, Amgen; speaker’s bureau: BMS, MSD, Pierre Fabre; research funding to institution: Immunocore, BMS, MSD, Amgen, AstraZeneca, Replimune. T.S. discloses advisory/consulting: Immunocore, Castle Biosciences; research funding to institution: Immunocore, Verastem.